Muchtar Eli, Wisniowski Brendan, Geyer Susan, Palladini Giovanni, Milani Paolo, Merlini Giampaolo, Schönland Stefan, Veelken Kaya, Hegenbart Ute, Leung Nelson, Dispenzieri Angela, Kumar Shaji K, Kastritis Efstathios, Dimopoulos Meletios A, Liedtke Michaela, Ulloa Patricia, Sanchorawala Vaishali, Szalat Raphael, Dooley Katharine, Landau Heather, Petrlik Erica, Lentzsch Suzanne, Coltoff Alexander, Bladé Joan, Cibeira M Teresa, Cohen Oliver, Foard Darren, Gillmore Jullian, Lachmann Helen, Wechalekar Ashutosh, Gertz Morie A
Division of Hematology, Mayo Clinic, Rochester, Minnesota.
National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England.
JAMA Oncol. 2024 Oct 1;10(10):1362-1369. doi: 10.1001/jamaoncol.2024.2629.
Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.
To validate graded kidney response criteria and their association with kidney and overall survival (OS).
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023.
Four kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response.
Cumulative incidence of progression to KRT and OS.
Seven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS.
The results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.
肾轻链(AL)淀粉样变性与进展至肾脏替代治疗(KRT)及死亡风险相关。多项研究表明,成功的抗克隆治疗后蛋白尿减少幅度越大,预后越好。
验证分级肾脏反应标准及其与肾脏和总生存期(OS)的关联。
设计、设置和参与者:这项回顾性多中心队列研究于2010年至2015年在10个淀粉样变性转诊中心进行,纳入了可评估肾脏反应且在诊断后12个月内至少达到血液学部分缓解的肾AL淀粉样变性患者。中位随访时间为69(54 - 88)个月。数据分析于2023年进行。
根据治疗前24小时尿蛋白(24小时UP)水平降低情况分为四类肾脏反应:完全缓解(kidCR,24小时UP≤200mg)、非常好的部分缓解(kidVGPR,24小时UP降低>60%)、部分缓解(kidPR,降低31% - 60%)和无反应(kidNR,降低≤30%)。在标志性时间点(6、12和24个月)及最佳肾脏反应时评估肾脏反应。
进展至KRT的累积发生率和OS。
纳入732例患者(335例女性[45.8%]),中位(四分位间距)年龄为63(55 - 69)岁。中位(四分位间距)基线24小时蛋白尿和估计肾小球滤过率分别为每24小时5.3(2.8 - 8.5)g和72(48 - 92)mL/min/1.73m²。在竞争风险分析中,早在治疗开始后6个月,进展至KRT的5年累积发生率随肾脏反应程度加深而降低(kidNR、kidPR、kidVGPR和kidCR分别为11%、12%、2.1%和0%;P = 0.002),并在12个月、24个月及最佳肾脏反应时保持。与kidPR/kidNR相比,在24个月及最佳反应时能够达到kidCR/kidVGPR的患者OS显著更好。肾脏进展定义为估计肾小球滤过率降低25%或更多,与进展至KRT的累积发生率和OS相关。
这项队列研究结果表明,分级肾脏反应标准为治疗肾AL淀粉样变性患者提供了具有临床和预后意义的信息。该反应标准可能根据24小时蛋白尿水平降低程度为肾脏生存提供参考,并显示出与kidPR/kidNR相比,能够达到kidCR/kidVGPR的患者具有OS优势。综上所述,最终改善肾脏和患者生存需要在12个月时至少达到kidVGPR。